Aptorum Group Limited is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic products aimed at infectious diseases and various cancers. Its operations are structured across Therapeutics and Non-Therapeutics segments. The company's robust pipeline includes SACT-1 for neuroblastoma and other cancer types; SACT-COV19 for coronavirus disease; ALS-4, designed to combat bacterial infections such as MRSA; and ALS-1 for Influenza A viral infections. Aptorum is also advancing ALS-2/3 for gram-positive bacterial infections, RPIDD as a molecular diagnostic for pathogens, the NativusWell DOI (NLS-2) dietary supplement, NLS-1 for endometriosis, DLS-1+2 for NSCLC with specific mutations, DLS-3 as an autoimmune small molecule, and CLS-1 for obesity. The company's innovative drug discovery relies on methods like systematic screening of existing approved drug molecules and microbiome-based research platforms, particularly for metabolic disorders. Beyond its current programs, Aptorum engages in therapeutic and diagnostic projects spanning neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. Additionally, it operates a medical clinic. Founded in 2010, Aptorum Group Limited maintains its headquarters in London, UK.